(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one
- CAS No.
- 854107-55-4
- Chemical Name:
- (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one
- Synonyms
- PonesiMod;CS-2358;CS-2110;ACT 128800;PONESIMOD,ACT-128800;ACT128800;ACT 128800;ACT-128800;(Z)-5-((Z)-3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one;(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one;5-[3-Chloro-4-[((2R)-2,3-dihydroxypropyl)oxy]benz-(Z)-ylidene]-2-((Z)-propylimino)-3-(o-tolyl)thiazolidin-4-one;(5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
- CBNumber:
- CB22598855
- Molecular Formula:
- C23H25ClN2O4S
- Molecular Weight:
- 460.97
- MDL Number:
- MFCD18207776
- MOL File:
- 854107-55-4.mol
- MSDS File:
- SDS
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one Properties
| Boiling point | 658.0±65.0 °C(Predicted) |
|---|---|
| Density | 1.30±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| form | A crystalline solid |
| pka | 13.38±0.20(Predicted) |
| FDA UNII | 5G7AKV2MKP |
| NCI Drug Dictionary | ponesimod |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one price More Price(19)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 22053 | Ponesimod ≥98% | 854107-55-4 | 1mg | $38 | 2024-03-01 | Buy |
| Cayman Chemical | 22053 | Ponesimod ≥98% | 854107-55-4 | 5mg | $172 | 2024-03-01 | Buy |
| Cayman Chemical | 22053 | Ponesimod ≥98% | 854107-55-4 | 10mg | $299 | 2024-03-01 | Buy |
| Cayman Chemical | 22053 | Ponesimod ≥98% | 854107-55-4 | 25mg | $586 | 2024-03-01 | Buy |
| TRC | P689490 | Ponesimod | 854107-55-4 | 500μg | $140 | 2021-12-16 | Buy |
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one Chemical Properties,Uses,Production
Uses
Ponesimod is an orally active sphingosine-1-phosphate receptor agonist. It protects against lymphocyte-mediated tissue inflammation.
Biological Activity
ec50: 5.7 nmponesimod is a sphingosine-1-phosphate receptor 1 (s1p1) modulator.lymphocyte exit from lymph nodes and its recirculation into blood is reported to be controlled by s1p. the cellular receptor mediating lymphocyte exit is one of five s1p receptors, s1p1. thus, the nonselective agonists for s1p1 lead to blood lymphocyte count reduction.
in vitro
previous study found that ponesimod could activate s1p1-mediated signal transduction with high potency. moreover, relative to the potency for s1p, the potency of ponesimod at human recombinant receptors was 4.4-fold higher for s1p1 and 150-fold lower for human s1p3. thus, ponesimod was 650-fold more selective for human s1p1 over s1p3 than the endogeneous ligand [1].
in vivo
animal study showed that the oral administration of ponesimod to rats resulted in a dose-dependent decrease of blood lymphocyte count, and the blood lymphocyte count returned to baseline within 48 h after discontinuation of ponesimod treatment. in addition, ponesimod prevented inflammatory cell accumulation, edema formation, as well as cytokine release in the skin of mice with delayed-type hypersensitivity. furthermore, in rats with adjuvant-induced arthritis, ponesimod could also prevent the increase in paw volume and joint inflammation [2].
References
[1] piali l, froidevaux s, hess p, nayler o, bolli mh, schlosser e, kohl c, steiner b, clozel m. the selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. j pharmacol exp ther. 2011 may;337(2):547-56.
[2] d'ambrosio d, freedman ms, prinz j. ponesimod, a selective s1p1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. ther adv chronic dis. 2016 jan;7(1):18-33.
(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32686 | 60 |
| Shochem(Shanghai) Co.,Ltd | 86-21-50800795 | info@shochem.com | CHINA | 288 | 58 |
| Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63711 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| AFINE CHEMICALS LIMITED | 0571-85134551 18958018566; | info@afinechem.com | China | 15377 | 58 |
| Wuhan Nutra Biotechnology Co.,Ltd | +8617786394783 | nutrabiotech@outlook.com | China | 300 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
| Wuhan Demeikai Biotechnology Co., Ltd | +8618942921723 | info@dmksw.xin | China | 723 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418684 +8618949823763 | sales@tnjchem.com | China | 25363 | 58 |
Related articles
- Ponesimod: Synthesis and Description
- Ponesimod was approved in 2021 for the treatment of relapsing forms of multiple sclerosis (MS). This medication is an orally a....
- Jan 17，2024
